Focus on central nervous system neoplasia

Cancer Cell

Volumn 1, Issue 2, 2002, Pages 125-128

  Louis, David N ^a   Pomeroy, Scott L ^b   Cairncross, J Gregory ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

CARCINOGENESIS; CENTRAL NERVOUS SYSTEM; HUMAN; MOLECULAR DYNAMICS; MOLECULAR GENETICS; NERVOUS SYSTEM TUMOR; NEUROFIBROMATOSIS; PRIORITY JOURNAL; REVIEW; TURCOT SYNDROME; WORLD HEALTH ORGANIZATION; ANIMAL; CENTRAL NERVOUS SYSTEM TUMOR; CLASSIFICATION; DISEASE MODEL; GENETICS; GLIOMA; MEDULLOBLASTOMA; METASTASIS; PATHOLOGY; PROGNOSIS;

ANIMALS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE MODELS, ANIMAL; GLIOMA; HUMANS; MEDULLOBLASTOMA; NEOPLASM METASTASIS; PROGNOSIS;

EID: 0036490612     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00040-5     Document Type: Review

References (23)

1. Barker, F.G., 2nd, Simmons, M.L., Chang, S.M., Prados, M.D., Larson, D.A., Sneed, P.K., Wara, W.M., Berger, M.S., Chen, P., Israel, M.A., and Aldape, K.D. (2001). EGFR overexpression and radiation response in glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 51, 410-418.
2. Biegel, J.A. (1999). Cytogenetics and molecular genetics of childhood brain tumors. Neuro-oncol. 1, 139-151.
3. Burger, P.C., Pearl, D.K., Aldape, K., Yates, A.J., Scheithauer, B.W., Passe, S.M., Jenkins, R.B., and James, C.D. (2001). Small cell architecture - a histological equivalent of EGFR amplification in glioblastoma multiforme? J. Neuropathol. Exp. Neurol. 60, 1099-1104.
4. Cairncross, J.G., Macdonald, D., Ludwin, S., Lee, D., Cascino, T., Buckner, J., Fulton, D., Dropcho, E., Stewart, D., Schold, C., et al. (1994). Chemotherapy for anaplastic oligodendroglioma. J. Clin. Oncol. 12, 2013-2021.
5. Cairncross, J.G., Ueki, K., Zlatescu, M.C., Lisle, D.K., Finkelstein, D.M., Hammond, R.R., Silver, J.S., Stark, P.C., Macdonald, D.R., Ino, Y., et al. (1998). Specific chromosomal losses predict chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 90, 1473-1479.
6. DeAngelis, L.M. (2001). Brain tumors. N. Engl. J. Med. 344, 114-123.
7. Gilbertson, R., Perry, R., Kelly, P., Pearson, A., and Lunec, J. (1997). Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 57, 3272-3280.
8. Herms, J., Neidt, I., Luscher, B., Sommer, A., Schurmann, P., Schroder, T., Bergmann, M., Wilken, B., Probst-Cousin, S., Hernaiz-Driever, P., et al. (2000). C-MYC expression in medulloblastoma and its prognostic value. Int. J. Cancer 89, 395-402.
9. Holland, E.G. (2001). Gliomagenesis: genetic alterations and mouse models. Nat. Rev. Genet. 2, 120-129.
10. Ino, Y., Betensky, R.A., Zlatescu, M.C., Sasaki, H., Macdonald, D.R., Stemmer-Rachamimov, A.O., Ramsay, D.A., Cairncross, J.G., and Louis, D.N. (2001). Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin. Cancer Res. 7, 839-845.
11. Kleihues, P., and Cavenee, W.K. (2000). World Health Organization Classification of Tumours of the Nervous System (Lyon: WHO/IARC).
12. Kunwar, S., Mohapatra, G., Bollen, A., Lamborn, K.R., Prados, M., and Feuerstein, B.G. (2001). Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res. 61, 7683-7688.
13. Louis, D.N., Posner, J.B., Jacobs, T., and Kaplan, R. (2000). Report of the brain tumor progress review group, http://prg.nci.nih.gov/brain/finalreport. html.
14. MacDonald, T.J., Brown, K.M., LaFleur, B., Peterson, K., Lawlor, C., Chen, Y., Packer, R.J., Cogen, P., and Stephan, D.A. (2001). Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat. Genet. 29, 143-152.
15. Maura, M.J., O'Dwyer, M., Heinrich, M.C., and Druker, B.J. (2002). STI571 : a paradigm of new agents for cancer therapeutics. J. Clin. Oncol. 20, 325-334.
16. Packer, R.J., Cogen, P., Vezina, G., and Rorke, L.B. (1999). Medulloblastoma: clinical and biologic aspects. Neuro-oncol. 1, 232-250.
17. Pomeroy, S.L., Tamayo, P., Gaasenbeek, M., Sturla, L.M., Angelo, M., McLaughlin, M.E., Kim, J.Y., Goumnerova, L.C., Black, P.M., Lau, C., et al. (2002). Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436-442.
18. Segal, R.A., Goumnerova, L.C., Kwon, Y.K., Stiles, C.D., and Pomeroy, S.L. (1994). Expression of the neurotrophin receptor TrkC is linked to afavorable outcome in medulloblastoma. Proc. Natl. Acad. Sci. USA 91, 12867-12871.
19. Smith, J.S., Perry, A., Borell, T.J., Lee, H.K., O'Fallon, J., Hosek, S.M., Kimmel, D., Yates, A., Burger, P.C., Scheithauer, B.W., and Jenkins, R.B. (2000). Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 18, 636-645.
20. Smith, J.S., Tachibana, I., Passe, S.M., Huntley, B.K., Borell, T.J., Iturria, N., O'Fallon, J.R., Schaefer, P.L., Scheithauer, B.W., James, C.D., et al. (2001). PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl. Cancer Inst. 93, 1246-1256.
21. Taipale, J., Chen, J., Cooper, M., Wang, B., Mann, R., Milenkovic, L., Scott, M., and Beachy, P. (2000). Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406, 1005-1009.
22. Wechsler-Reya, R., and Scott, M.P. (2001). The developmental biology of brain tumors. Annu. Rev. Neurosci. 24, 385-428.
23. Yung, W.K., Prados, M.D., Yaya-Tur, R., Rosenfeld, S.S., Brada, M., Friedman, H.S., Albright, R., Olson, J., Chang, S.M., O'Neill, A.M., et al. (1999). Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 17, 2762-2771.